Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Anastrozole and Berberine Interaction: Avoid | Peptide Database

Compound Profiles Anastrozole Aromatase Inhibitor | Estrogen Management Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Berberine

Plant Alkaloid | Natural Glucose & Lipid Management

Berberine's primary mechanism of action involves activation of AMP-activated protein kinase (AMPK), the cell's master energy-sensing enzyme. Unlike metformin, which activates AMPK primarily through inhibition of mitochondrial Complex I, berberine appears to activate AMPK through multiple pathways, including direct inhibition of mitochondrial Complex I, stimulation of AMPK phosphorylation, and modulation of the AMP-to-ATP ratio.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Anastrozole with Berberine?

Combining Anastrozole with Berberine is not recommended. Both Anastrozole and Berberine carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anastrozole and Berberine safe together?

This combination carries significant risk. Both Anastrozole and Berberine carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anastrozole and Berberine?

Both Anastrozole and Berberine carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anastrozole and Berberine?

Anastrozole has a half-life of ~40-50 hours and Berberine has a half-life of ~4 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching PE-22-28 — share findings, ask questions, and learn from real experiences Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects. Selectively blocks TREK-1 potassium channels (IC50: 0.12 nM). Enhances serotonin neurotransmission in dorsal raphe nucleus, triggering CREB activation and hippocampal neurogenesis.

Source: peptide-db.com ↗

Research Indications

Protects blood vessels from age-related deterioration through gene expression regulation. Limits development of atherosclerotic plaques in blood vessels. Decreases endothelial dysfunction that contributes to cardiovascular disease. Regulates sirtuin 1 levels, mimicking some benefits of calorie restriction. Enhances mesenchymal stem cell proliferation and reduces senescence. Reverses senescence-associated secretory phenotype in aging cells.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

BAM-15 is orally bioavailable and is typically administered as an oral supplement in tablet or capsule form. Research in mice used dietary supplementation (0.1% of diet) or oral gavage dosing. Human dosing protocols are still being established through ongoing research. The compound has a relatively short half-life, which researchers are working to improve through structural modifications. Metabolic enhancement 25-50 mg Once or twice daily Oral Research protocol (mouse equivalent) ~10 mg/kg Daily Oral gavage

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →